AI diagnostics company Renalytix has reported a 30% rise in annual revenues to $3 million for the year ended 30 June 2025, driven by growing adoption of its FDA-approved and Medicare-reimbursed kidneyintelX.dkd test for early-stage chronic kidney disease. 

The London-listed MedTech achieved a 54% reduction in EBITDA losses through tighter cost controls, improved margins and operational efficiencies, while also completing oversubscribed fundraises totalling £18.5m over the past 12 months.

Partnerships with Tempus AI and MVP Health Care have expanded access to kidneyintelX.dkd testing across the US, with over 18,000 patients tested to date. 

With Medicare now reimbursing $931 per test, the business said it expects to strengthen financial resilience and scale national access as it moves into FY2026, targeting new US regions including Arizona, Florida, Texas and New York.